文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

靶向NDC80的T细胞受体模拟CAR T细胞对实体瘤和血液系统恶性肿瘤具有广泛反应性

A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies.
PubMed 文献 · Blood · 2022-01-01

研究通过质谱法从8种血液和非血液肿瘤细胞系HLA配体中鉴定出源自NDC80基因、受HLA-A*02限制的共享配体ALNEQIARL;针对该复合物的T细胞受体模拟CAR T细胞对多种肿瘤(尤其血液肿瘤)表现出高灵敏度和特异性杀伤,并在小鼠模型中对人白血病和实体瘤有效,且对静息或活化健康白细胞及造血干细胞无毒性。

要点

  • 质谱法鉴定出NDC80来源的HLA-A*02限制性配体ALNEQIARL。
  • 靶向ALNEQIARL:HLA-A*02的CAR T细胞对多种肿瘤表现高灵敏度和特异性。
  • 该CAR T细胞在小鼠模型中对人白血病和实体瘤有效且对健康造血细胞无毒性。

核心结论

  • 质谱法可指导设计广泛反应性治疗性T细胞受体模拟CAR T细胞疗法,靶向目前小分子、常规CAR T细胞、T细胞或抗体无法成药的多种癌症类型。

研究设计与样本

  • 对8种血液和非血液肿瘤细胞系进行HLA配体质谱分析,鉴定共享配体。
  • 构建针对ALNEQIARL:HLA-A*02复合物的CAR T细胞,体外评估灵敏度和特异性,并在小鼠模型中测试对人白血病和实体瘤的疗效。

主要发现

  • 质谱鉴定出源自NDC80基因、受HLA-A*02限制的共享非免疫原性配体ALNEQIARL。
  • 靶向ALNEQIARL:HLA-A*02的CAR T细胞对多种癌症类型(尤其血液来源)表现出高灵敏度和特异性识别与杀伤。
  • 该CAR T细胞在小鼠模型中对人白血病和实体瘤有效。
  • 对静息或活化健康白细胞及造血干细胞未观察到毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Target identification for chimeric antigen receptor (CAR) T-cell therapies remains challenging due to the limited repertoire of tumor-specific surface proteins. Intracellular proteins presented in the context of cell surface HLA provide a wide pool of potential antigens targetable through T-cell receptor mimic antibodies. Mass spectrometry (MS) of HLA ligands from 8 hematologic and nonhematologic cancer cell lines identified a shared, non-immunogenic, HLA-A*02-restricted ligand (ALNEQIARL) derived from the kinetochore-associated NDC80 gene. CAR T cells directed against the ALNEQIARL:HLA-A*02 complex exhibited high sensitivity and specificity for recognition and killing of multiple cancer types, especially those of hematologic origin, and were efficacious in mouse models against a human leukemia and a solid tumor. In contrast, no toxicities toward resting or activated healthy leukocytes as well as hematopoietic stem cells were observed. This shows how MS can inform the design of broadly reactive therapeutic T-cell receptor mimic CAR T-cell therapies that can target multiple cancer types currently not druggable by small molecules, conventional CAR T cells, T cells, or antibodies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Klatt MG, Dao T, Yang Z, et al. A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies. Blood. 2022. PMID: 35427421. doi:10.1182/blood.2021012882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。